Document:

EXHIBIT 10.1

 

CONVERTIBLE PROMISSORY NOTE

 

	$__________    	 	Cambridge, Massachusetts 
	 	 	Date: ___________ 

 

For value received, the undersigned, Pathfinder Cell Therapy,
Inc., a Delaware corporation (the “ Borrower ”), hereby unconditionally promises to pay to the order of _____________
(the “ Payee ”), the principal sum of   $_______   and   00/100   Dollars
  ($_________ ), together with interest to maturity (whether by lapse of time, acceleration or otherwise) on the
balance of principal remaining from time to time outstanding at a rate per annum equal to 6%. Interest shall be calculated on the
basis of a 360-day year and actual days.

 

The outstanding principal amount, together with accrued interest,
of this Promissory Note shall become due and payable on the first anniversary of the date hereof.

 

Payee may elect, at any time prior
to completion or termination of the Capital Raise (defined below), upon written notice to Borrower, to convert all or a
portion of the outstanding principal and/or interest hereof, to shares of common stock of the Borrower, for the subscription
price thereof, in the Capital Raise.  “Capital Raise” has the meaning used in that certain agreement
and plan of merger dated December 22, 2010 (as amended) by and among Borrower, a wholly-owned subsidiary of Borrower, and
Pathfinder, LLC, a Massachusetts limited liability company, pursuant to which Borrower acquired Pathfinder, LLC in a merger
transaction, the initial closing of which Capital Raise occurred in September 2011 immediately after the merger. As a
condition to any such conversion, Payee shall execute and deliver to Borrower such agreements and documentation as Borrower
requires of other investors in the Capital Raise.

 

The Borrower shall have the right to prepay, at any time,
all or any portion of the principal indebtedness evidenced by this Note, together with any accrued interest.

 

No failure by the holder of this Note to exercise, and no
delay in exercising, any right or power hereunder shall operate as a waiver thereof, nor shall any single or partial exercise by
such holder of any right or power preclude any other or further exercise thereof or the exercise of any other right or power.  The
rights and remedies of the holder hereof as herein specified are cumulative and not exclusive of any other rights or remedies which
such holder may otherwise have.

 

The undersigned agrees to pay all costs
and expenses incurred by the holder hereof in enforcing this Note, including, without limitation, reasonable attorneys’
fees and disbursements.

 

    	 

    	 

    

 

Every maker, endorser and guarantor of this Note hereby waives
presentment, demand and protest, and consents to any and all extensions and other indulgences granted by the holder hereof and
agrees that no such extensions or other indulgences granted by the holder, and no discharge or release of any other party primarily
or secondarily liable on this Note, or of any collateral securing this Note, shall operate to discharge the indebtedness evidenced
by this Note.  If this Note is signed by more than one person, all references to the Borrower shall apply to each of
them and their liabilities hereunder shall be joint and several.

 

Any notice of non-payment shall be deemed given when delivered
in hand or when mailed, postage prepaid, by certified or registered mail, return receipt requested to the Borrower at 12 Bow Street,
Cambridge, Massachusetts 02138 or sent thereto by Federal Express or comparable overnight courier.

 

This Note shall be governed and construed in accordance with
the laws of the State of New York applicable to contracts made and to be performed therein (excluding choice of law principles).

 

IN WITNESS WHEREOF, the undersigned has executed or caused
this Note to be executed under seal as of the year and day first written above.

 

	WITNESS 
    	 	PATHFINDER
    CELL THERAPY, INC. 
	 	 	 	 
	  	 	By:	 
	 	 	 	Richard
    L. Franklin, CEO 

 

    	2

    	 

    

 

	Schedule of Promissory Notes
	 	 	 	 	 	 
	Date of issuance	 	Note Holder	 	 	Principal amount 	 
	 	 	 	 	 	 	 
	February 2, 2012	 	Falcon Corporate Investments Limited	 	$	150,000	 
	 	 	 	 	 	 	 
	February 29, 2012	 	Falcon Corporate Investments Limited	 	$	170,000	 
	 	 	 	 	 	 	 
	March 15, 2012	 	Falcon Corporate Investments Limited	 	$	250,000	 
	 	 	 	 	 	 	 
	April 23, 2012	 	Falcon Corporate Investments Limited	 	$	150,000	 
	 	 	 	 	 	 	 
	May 25, 2012	 	Skye Asset Management SA	 	$	270,000	 
	 	 	 	 	 	 	 
	June 20, 2012	 	Ventura, Inc.	 	$	225,000	 
	 	 	 	 	 	 	 
	July 27, 2012	 	Ventura, Inc.	 	$	50,000	 
	 	 	 	 	 	 	 
	August 17, 2012	 	Breisgau Bio Ventures SA	 	$	100,000	 
	 	 	 	 	 	 	 
	October 1, 2012	 	Breisgau Bio Ventures SA	 	$	200,000	 
	 	 	 	 	 	 	 
	October 23, 2012	 	Breisgau Bio Ventures SA	 	$	200,000	 
	 	 	 	 	 	 	 
	November 20, 2012	 	Breisgau Bio Ventures SA	 	$	70,000	 
	 	 	 	 	 	 	 
	December 4, 2012	 	Breisgau Bio Ventures SA	 	$	70,000	 
	 	 	 	 	 	 	 
	December 21, 2012	 	Breisgau Bio Ventures SA	 	$	60,000	 
	 	 	 	 	 	 	 
	January 9, 2013	 	Breisgau Bio Ventures SA	 	$	75,000	 
	 	 	 	 	 	 	 
	January 28, 2013	 	Breisgau Bio Ventures SA	 	$	130,000	 
	 	 	 	 	 	 	 
	March 4, 2013	 	Mr. Joerg Gruber	 	$	100,000	 
	 	 	 	 	 	 	 
	April 2, 2013	 	Ventura, Inc.	 	$	150,000	 
	 	 	 	 	 	 	 
	April 29, 2013	 	Ventura, Inc.	 	$	150,000	 
	 	 	 	 	 	 	 
	 May 28, 2013	 	Breisgau Bio Ventures SA	 	$	250,000	 
	 	 	 	 	 	 	 
	June 26, 2013	 	Breisgau Bio Ventures SA	 	$	150,000	 
	 	 	 	 	 	 	 
	July 24, 2013	 	Breisgau Bio Ventures SA	 	$	170,000	 

 

    	3

    	 

    

 

	August 24, 2013	 	Breisgau Bio Ventures SA	 	$	100,000	 
	 	 	 	 	 	 	 
	September 26, 2013	 	Breisgau Bio Ventures SA	 	$	100,000	 
	 	 	 	 	 	 	 
	October 22, 2013	 	Breisgau Bio Ventures SA	 	$	135,000	 
	 	 	 	 	 	 	 
	November 22, 2013	 	Breisgau Bio Ventures SA	 	$	100,000	 
	 	 	 	 	 	 	 
	December 20, 2013	 	Breisgau Bio Ventures SA	 	$	125,000	 
	 	 	 	 	 	 	 
	January 21, 2014	 	Breisgau Bio Ventures SA	 	$	105,000	 
	 	 	 	 	 	 	 
	February 24, 2014	 	Breisgau Bio Ventures SA	 	$	120,000	 
	 	 	 	 	 	 	 
	March 25, 2014	 	Breisgau Bio Ventures SA	 	$	105,000	 
	 	 	 	 	 	 	 
	April 24, 2014	 	Ventura, Inc.	 	$	100,000	 
	 	 	 	 	 	 	 
	May 28, 2014	 	Ventura, Inc.	 	$	120,000	 
	 	 	 	 	 	 	 
	June 5, 2014	 	Ventura, Inc.	 	$	30,000	 
	 	 	 	 	 	 	 
	June 26, 2014	 	Ventura, Inc.	 	$	50,000	 
	 	 	 	 	 	 	 
	August 5, 2014	 	Ventura, Inc.	 	$	50,000	 
	 	 	 	 	 	 	 
	August 21, 2014	 	Ventura, Inc.	 	$	100,000	 
	 	 	 	 	 	 	 
	September 25, 2014	 	Ventura, Inc.	 	$	80,000	 
	 	 	 	 	 	 	 
	October 24, 2014	 	Ventura, Inc.	 	$	35,000	 
	 	 	 	 	 	 	 
	November 28, 2014	 	Ventura, Inc.	 	$	60,000	 
	 	 	 	 	 	 	 
	December 30, 2014	 	Ventura, Inc.	 	$	50,000	 
	 	 	 	 	 	 	 
	February 2, 2015	 	Ventura, Inc.	 	$	75,000	 
	 	 	 	 	 	 	 
	March 5, 2015	 	Ventura, Inc.	 	$	55,000	 
	 	 	 	 	 	 	 
	March 27, 2015	 	Breisgau Bio Ventures SA	 	$	55,000	 
	 	 	 	 	 	 	 
	May 11, 2015	 	Breisgau Bio Ventures SA	 	$	50,000	 
	 	 	 	 	 	 	 
	June 5, 2015	 	Breisgau Bio Ventures SA	 	$	42,000	 
	 	 	 	 	 	 	 
	July 16, 2015	 	Breisgau Bio Ventures SA	 	$	75,000	 
	 	 	 	 	 	 	 
	 	 	Aggregate Principal amount	 	$	5,057,000	 

 

 

4Exhibit

Exhibit 10.1

REPRESENTATIONS, WARRANTIES AND AGREEMENTS
OF
COHEN & STEERS CAPITAL MANAGEMENT, INC.
The undersigned hereby certifies to Brandywine Realty Trust, a Maryland real estate investment trust (the “Company”), that he is the duly appointed Executive Vice President of Cohen & Steers Capital Management, Inc., a New York corporation (“C&S”), and on behalf of C&S, pursuant to due authorization, does further hereby certify, represent, warrant, and agree that:
		
	1.
	C&S understands that the representations, warranties and agreements contained herein are made in order to obtain an exception for C&S to the ownership limitations (the “Ownership Limit”) set forth in the Declaration of Trust, as amended to date (the “Articles”), of the Company.  Such exception, which is sought with respect to the common shares of beneficial interest of the Company (the “Common Shares”) and the series of preferred shares of beneficial interest of the Company designated “6.90% Series E Cumulative Redeemable Preferred Shares” (the “Series E Preferred Shares” and, together with the Common Shares, the “Shares”), will allow C&S to be a “beneficial owner,” as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (a “Rule 13d-3 Owner”), of up to, but not in excess of, 15.0% of the value of all outstanding Shares (the “C&S Shares”).

		
	2.
	C&S’s ownership, as a Rule 13d-3 Owner, of the C&S Shares will not result in any Individual being the Tax Owner of Shares in excess of 9.8% of the value of all outstanding Shares.  As used herein, the term “Tax Owner” of Shares shall mean the person who is considered to own such Shares applying the rules of Section 856(h) of the Internal Revenue Code of 1986 (the “Code”), including the relevant provisions of Section 542(a)(2) and Section 544 as modified by Section 856(h) of the Code.   The term “Individual” shall mean a natural person or an organization treated as an individual under the provisions of Section 542(a)(2) of the Code, applying the relevant rules of Section 856(h) of the Code.  

		
	3.
	Neither C&S nor any Investor owns directly or indirectly any stock or other equity interest in excess of 9.8% in any Tenant.  The term “Investor” means any owner of C&S or any open-end or closed-end fund for which C&S or an affiliate acts as an investment advisor.  The term “Tenant” means any entity that leases space from the Company or from any direct or indirect subsidiary partnership, corporation or limited liability company in which Company owns an interest.  C&S shall notify the Company in the event that C&S or any Investor acquires any stock or other equity interest in excess of 9.8% in any Tenant.

		
	4.
	C&S will not dispose of any of the C&S Shares in violation of the Ownership Limit or in a manner that would cause any Individual to be the Tax Owner of more than 9.8% of the value of all outstanding Shares.

		
	5.
	C&S agrees that if, for any reason, (i) any of the above representations or warranties is violated, (ii) the ownership, as a Rule 13d-3 Owner, of the C&S Shares causes any Individual to be the Tax Owner of more than 9.8% of the value of all outstanding Shares, 

(iii)  C&S or any Investor acquires any stock or other equity interest in excess of 9.8% in any Tenant, or (iv) in the sole reasonable judgment of the Company, the ownership, as a Rule 13d-3 Owner, of the C&S Shares could otherwise jeopardize the Company’s tax status as a real estate investment trust for federal income tax purposes, then the waiver of the ownership limits granted by the Company to C&S shall be deemed void ab initio and shall result in a conversion of all or a portion (as reasonably determined by the Company to be necessary) of the C&S Shares into Excess Shares under the Articles.
		
	6.
	C&S understands that the foregoing exception to the Ownership Limit is only being granted to C&S, and not to any other person (including any of the Investors).

		
	7.
	C&S agrees that solely with respect to any Shares for which C&S is the beneficial owner as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended, in excess of 9.8% of the value of all outstanding Shares, C&S shall not take any actions that are inconsistent with its status as an investment manager that is eligible to file a Form 13G under the Securities Exchange Act of 1934 including the following:

		
	a.
	Solicit proxies from shareholders of the Company, become a “participant” in any “election contest” (as such terms are used in Rule 14a-11 of the Securities Exchange Act of 1934, as amended), with respect to the Company, or make any communication (other than as required by law) referred to in Rule 14a-1(l)(2)(iv) of the Securities Exchange Act of 1934, as amended, in connection with any election contest or other vote by shareholders of the Company or otherwise;

		
	b.
	Vote for the removal of any member of the Board, except removal “for cause” as such term is used under Maryland law, except that this shall not limit C&S’s ability to vote against the reelection of a Board member;

		
	c.
	Call or seek to have called any meeting of the shareholders of the Company;

		
	d.
	Otherwise act, alone or in concert with others to (i) solicit, propose, seek to effect or negotiate with any other person with respect to (A) any business combination with the Company or (B) any restructuring, recapitalization or similar transaction of the Company, (ii) solicit, propose, seek to effect or negotiate with any other person with respect to, or announce an intent to make, any tender offer or exchange offer for any voting securities of the Company, or (iii) assist, participate in, facilitate or solicit any effort or attempt by any persons to do or seek to do any of the foregoing.

		
	8.
	C&S has not violated any of the terms of the Representations, Warranties and Agreements executed as of June 27, 2003 (the “2003 Waiver”) and such 2003 Waiver shall automatically be superseded by this document. 

		
	9.
	The undersigned has the authority to execute this document on behalf of C&S.

 2

IN WITNESS WHEREOF, I have executed this certificate as of this 10th day of August, 2015.

Cohen & Steers Capital Management, Inc.
	
			
	By:  
	/s/ Thomas Bohjalin

	 
	Thomas Bohjalian

	 
	 

	 
	Executive Vice President

 

 3

WAIVER OF OWNERSHIP LIMITS
[BRANDYWINE REALTY TRUST LETTERHEAD]

August 10, 2015
Cohen & Steers Capital Management, Inc.
280 Park Avenue
New York, New York 10017

Re:    Share Ownership Limits
Reference is made to the Representations, Warranties and Agreements executed as of August 10, 2015 of Cohen & Steers Capital Management, Inc. (“C&S”) to Brandywine Realty Trust (the “Company”), containing certain representations, warranties and agreements, a copy of which is attached to this letter as Attachment I (the “Representation Letter”).  Based upon the Representation Letter, the Company hereby advises you that an exception to the Ownership Limit referred to in the Representation Letter has been established for C&S under the Declaration of Trust of the Company effective as the date received on and subject to the terms, conditions and limitations set forth in the Representation Letter.  The foregoing exception to the Ownership Limit supersedes the exception granted by the Company to C&S in a letter dated June 27, 2003 from the Company to C&S.

Very truly yours, 
	
			
	BRANDYWINE REALTY TRUST

	By:  
	/s/ Gerard H. Sweeney  

	 
	Name: Gerard H. Sweeney 

	 
	Title: President and Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]